Free lookups: 2/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
2 of 3 free lookups remaining Upgrade
New search Medicine profile Oxytocin / Ergometrine

Clinical medicine profile

Oxytocin / Ergometrine

Adrenocorticotropic Hormone [EPC], Oxytocic [EPC], Thyroid Stimulating Hormone [EPC]

POM
Evidence state Source-linked Review date not recorded
Route
See product SmPC
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • [Oxytocin] Hypersensitivity to the active substance or excipients.
  • Additional absolute contraindications are indication- and product-specific — consult SmPC. [Ergometrine] Hypersensitivity to the active substance or excipients.
  • Additional absolute contraindications are indication- and product-specific — consult SmPC.

Precautions

  • WARNINGS Stop use and ask doctor if symptoms persist more than 5 days.
  • If pregnant or breast-feeding ask a health professional before use.
  • Keep out of reach of children.
  • In case of overdose, get medical help or contact a Poison Control Center right away.
  • Contains ethyl alcohol 30%
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

DIRECTIONS Take 15 minutes before meals Adults : 20 drops in a little water, 2 times per day

Paediatric

See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.

Renal

Review renal impairment dosing; many agents need CrCl/eGFR adjustment.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.

03 Clinical use

Use, effects & interactions

Indications

  • Therapeutic use is agent- and indication-specific within the class (Therapeutic agent (verify pharmacological class)).
  • Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.
  • Post-partum uterine haemorrhage

Adverse effects

  • [From component Oxytocin] Fibrinogenaemia
  • pelvic haematoma
  • postpartum haemorrhage: allergic reactions
  • cardiac arrhythmias
  • hypotension followed by hypertension
  • uterine rupture
  • water intoxication
  • vomiting.
  • Professional use: confirm indication, dose, duration, monitoring and patient counselling points against current Kenya STG / EML and the product SmPC.
  • Document allergy status and key interactions.
04 Pharmacology

Mechanism & disposition

Combination product.

Combination product.Component mechanism (Oxytocin): It acts by…It induces lactation by stimulating smooth…
Read complete mechanism

Combination product. Component mechanism (Oxytocin): It acts by increasing intracellular calcium concentrations in the uterine myometrium, which contains receptors specific to oxyto- cin, thus inducing contractions. It induces lactation by stimulating smooth muscle to help dis- charge of milk from breasts

Onset

Product-specific

Duration

Product-specific

Route

See product SmPC

Elimination

are product-specific. Consider food effects, protein binding, hepatic CYP/UGT

Half-life

when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.

05 Special populations

Pregnancy, lactation & diet

Pregnancy

[Oxytocin] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist. [Ergometrine] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.

Lactation

[Oxytocin] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data. [Ergometrine] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.

06 Kenya market

Brands & loaded prices

From—
Median—
Listings0
BrandManufacturerPackObserved price
No reviewed brand listings are linked yet.
07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; FDA drug label via OpenFDA/DailyMed; RxNorm (NLM RxNav); PubChem
Last reviewedNot recorded
EvidenceSource-linked
Open source document ↗

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.